3.32  0.34 (11.41%)		10-24 16:00
Open: 2.97 High: 3.44 Volume: 630,621		Pre. Close: 2.98 Low: 2.92 Market Cap: 45(M)

Short term
Mid term
Targets	6-month :	3.99	1-year :	4.66
Resists	First :	3.42	Second :	3.99
Pivot price	2.97
Supports	First :	2.81	Second :	2.44
MAs	MA(5) :	3.02	MA(20) :	2.9
	MA(100) :	2.58	MA(250) :	5.4
MACD	MACD :	0.1	Signal :	0
%K %D	K(14,3) :	60.5	D(3) :	54.1
RSI	RSI(14): 66.8
52-week	High :	17.92	Low :	1.7

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ OKUR ] has closed above the upper band by 17.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 17.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.42 - 3.44	3.44 - 3.45
Low:	2.89 - 2.9	2.9 - 2.92
Close:	3.3 - 3.32	3.32 - 3.34

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

Wed, 22 Oct 2025
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), OnKure Therapeutics (OKUR) and BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail

Wed, 24 Sep 2025
OnKure Therapeutics CEO Saccomano sells $230 in stock - Investing.com

Tue, 19 Aug 2025
Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky - Yahoo Finance

Tue, 12 Aug 2025
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire

Wed, 23 Jul 2025
Is OnKure Therapeutics (NASDAQ:OKUR) In A Good Position To Deliver On Growth Plans? - simplywall.st

Tue, 06 May 2025
OnKure Therapeutics Reports Progress in PIKture-01 Trial and Financial Results for Q1 2025 - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	13 (M)
Shares Float	6 (M)
Held by Insiders	1.7 (%)
Held by Institutions	87.1 (%)
Shares Short	175 (K)
Shares Short P.Month	198 (K)

EPS	-4.47
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.78
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-71 %
Return on Equity (ttm)	-142.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-4.9
Qtrly Earnings Growth	0 %
Operating Cash Flow	-61 (M)
Levered Free Cash Flow	-32 (M)

PE Ratio	-0.75
PEG Ratio	0
Price to Book value	0.57
Price to Sales	0
Price to Cash Flow	-0.7

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.